

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		Docket Number (Optional) 5197-103 US	Application Number 10/826,240
		Applicant(s) DUCHARME et al.	
		Filing Date 04/15/2004	Group Art Unit 3762
*EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
		http://www.aboutatrialfibrillation.com/whatisaf.html	
/A.P./	1		
/A.P./	2	CARSON, Peter E. et al., "The Influence of Atrial Fibrillation on Prognosis in Mild to Moderate Heart Failure - The V-HeFT Studies", Circulation, Supplement VI, 87:6, pp VII02-VII10, (June 1993);	
/A.P./	3	MIDDLEKAUFF, Holly R. et al., "Prognostic Significance of Atrial Fibrillation in Advanced Heart Failure - A Study of 390 Patients", Circulation, 84:1, pp 40-48, (July 1991);	
/A.P./	4	POZZOLI, Massimo et al., "Predictors of Primary Atrial Fibrillation and Concomitant Clinical and Hemodynamic Changes in Patients With Chronic Heart Failure: A Prospective Study in 344 Patients With Baseline Sinus Rhythm", JACC, 32:1, pp 197-204, (July 1998);	
/A.P./	5	DRIES, Daniel L. et al., "Atrial Fibrillation Is Associated With an Increased Risk for Mortality and Heart Failure Progression in Patients With Asymptomatic and Symptomatic Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SOLVD Trials", JACC, 32:3, pp 695-703, (September 1998);	
/A.P./	6	BOURASSA, Martial G. et al., "Natural History and Patterns of Current Practice in Heart Failure", JACC, Supplement A, 22:4, pp 14A-19A, (October 1993);	
/A.P./	7	MATHEW, James et al., "Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias, in Congestive Heart Failure", CHEST, 118:4, 914-922, (October 2000);	
/A.P./	8	LI, Danshi et al., "Promotion of Atrial Fibrillation by Heart Failure in Dogs - Atrial Remodeling of a Different Sort", Circulation, 100, pp 87-95, (July 6, 1999);	
/A.P./	9	SHI, Yanfen et al., "Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation", Cardiovascular Research, 52, pp 219-225, (2001);	
/A.P./	10	LI, Danshi et al., "Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing-Induced Congestive Heart Failure", Circulation, 104, pp 2608-2614, (November 20, 2001);	
/A.P./	11	SHI, Yanfen et al., "Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure", Cardiovascular Research, 54, pp 456-461, (2002);	
/A.P./	12	THE SOLVD INVESTIGATORS, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure", The New England Journal of Medicine, 325:5, pp 293-302, (August 1, 1991);	
EXAMINER /Anna Pagonakis/		DATE CONSIDERED 09/18/2007	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number	
		5197-103 US		10/862,240
		Applicant(s)		Group Art Unit
		DUCHARME et al.		
		Filing Date	Group Art Unit	
		04/15/2004	3762	

*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
/A.P./	13	THE SOLVD INVESTIGATORS, "Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions", The New England Journal of Medicine, 327:10, pp 685-691, (September 3, 1992);
/A.P./	14	THE SOLVD INVESTIGATORS, "Studies of Left Ventricular Dysfunction (SOLVD) - Rationale, Design and Methods: Two Trials That Evaluate the Effect of Enalapril on Patients with Reduced Ejection Fraction", The American Journal of Cardiology, 66, pp 315-322, (August 1, 1990);
/A.P./	15	FUSTER, Valentin et al., "ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary", JACC, 38:4, pp 1231-1265, (October 2001);
/A.P./	16	ST. JOHN SUTTON, Martin et al., "Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction - The Protective Effects of Captopril", Circulation, 89:1, pp 68-75, (January 1994);
/A.P./	17	ZOU, Yunzeng et al., "Cell Type-Specific Angiotensin II-Evoked Signal Transduction Pathways - Critical Roles of G Subunit, Src Family, and Ras in Cardiac Fibroblasts", Circ. Res., 82, pp 337-345, (1998);
/A.P./	18	PAGES, Gilles et al., "Mitogen-activated protein kinases p42 and p44 are required for fibroblast proliferation", Proc. Nat. Acad. Sci., 90, pp 8319-8323, (September 1993);
/A.P./	19	BRILLA, Christian G. et al., "Collagen Metabolism in Cultured Adult Rat Cardiac Fibroblasts: Response to Angiotensin II and Aldosterone", J. Mol. Cell Cardiol., 26, pp 809-820, (1994);
/A.P./	20	GOETTE, Andreas et al., "Increased Expression of Extracellular Signal-Regulated Kinase and Angiotensin-Converting Enzyme in Human Atria During Atrial Fibrillation", JACC, 35:6, pp 1669-1677, (May 2000);
/A.P./	21	GOTTE, Andreas et al., "Regulation of Angiotensin II Receptor Subtypes During Atrial Fibrillation in Humans", Circulation, 101, pp 2678-2681, (June 13, 2000);
/A.P./	22	NAKASHIMA, Hideko et al., "Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation", Circulation, 101, pp 2612-2617, (June 6, 2000);
/A.P./	23	KAPRIELIAN, Raffi R. et al., "Angiotensin II Receptor Type 1 mRNA is Upregulated in Atria of Patients with End-stage Heart Failure", J. Mol. Cell. Cardiol., 29, pp 2299-2304, (1997);
/A.P./	24	SOLTI, F. et al., "The effect of atrial dilatation on the genesis of atrial arrhythmias", Cardiovascular Research, 23, pp 882-886, (1989);

EXAMINER	DATE CONSIDERED
/Anna Pagonakis/	09/18/2007


*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 5197-103 US	Application Number 10/826,240
		Applicant(s) DUCHARME et al.	
		Filing Date 04/15/2004	Group Art Unit 3762


*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
/A.P./	25	RAVELLI, Flavia et al., "Effects of Atrial Dilatation on Refractory Period and Vulnerability to Atrial Fibrillation in the Isolated Langendorff-Perfused Rabbit Heart", Circulation, 96:5, pp 1686-1695, (September 2, 1997);
/A.P./	26	WEBSTER, Mark W.I. et al., "Effect of Enalapril on Ventricular Arrhythmias in Congestive Heart Failure", The American Journal of Cardiology, 56, pp 566-569, (September 15, 1985);
/A.P./	27	MADRID, Antonio H. et al., "Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation - A Prospective and Randomized Study", Circulation, 106, 331-336, (July 16, 2002);
/A.P./	28	LAMASSA, Maria et al., "Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe: Data From a Multicenter Multinational Hospital-Based Registry (The European Community Stroke Project)", Stroke, 32, pp 392-398, (February 2001);
/A.P./	29	BOSCH, Jackie et al., "Use of ramipril in preventing stroke: double blind randomised trial", BMJ, 324, pp 1-5, (March 23, 2002);
/A.P./	30	SHINAGAWA, Kaori et al., "Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs", Circulation, 105, pp 2672-2678, (June 4, 2002);
/A.P./	31	UENG, Kwo-Chang et al., "Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation - Results of a prospective and controlled study", European Heart Journal, 24, pp 2090-2098, (2003);
/A.P./	32	THE AF-CHF TRIAL INVESTIGATORS, "Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial", American Heart Journal, 144:4 pp 597-607, (October 2002);
/A.P./	33	THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", The New England Journal of Medicine, 342:3, pp 145-153, (January 20, 2000).

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 09/18/2007
----------------------------------	-----------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 <p>INFORMATION DISCLOSURE CITATION (use several sheets if necessary)</p>				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240		
				APPLICANT(S) DUCHARME et al.				
				FILING DATE 04/15/2004		GROUP ART UNIT 3762		
				U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
I.A.P./		Van Den Berg et al., "Effects of Lisinopril in Patients with Heart Failure and Chronic Atrial Fibrillation," J Cardiac Failure 1(5):355-63 (1995)						
I.A.P./		Van Noord et al., "Pre-Treatment with ACE Inhibitors Enhances Cardioversion Outcome in Patients with Persistent Atrial Fibrillation," Abstracts From Scientific Sessions 104(17 sup):II-699 (2001)						
EXAMINER /Anna Pagonakis/				DATE CONSIDERED 09/18/2007				
<p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>								

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> <div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; margin: 10px auto; display: flex; align-items: center; justify-content: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: 8px;">PATENT & TRADEMARK OFFICE</div> <div style="text-align: center;"> AUG 20 2004 </div> </div>				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240		
				DUCHARME et al.				
				FILING 04/15/2004		GROUP ART 3762		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
/A.P./		Stevenson et al., "Improving Survival for Patients with Atrial Fibrillation and Advanced Heart Failure," JACC 28(6):1458-63 (1996)						
/A.P./		Vermes et al., "Enalapril Decreases the Incidence of Atrial Fibrillation in Patients with Left Ventricular Dysfunction," Circulation 107:2926-2931 (2003)						
EXAMINER /Anna Pagonakis/				DATE CONSIDERED 09/18/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small> 				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240		
				DUCHARME et al.				
				FILING 04/15/2004		GROUP ART 3762		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
I.A.P./		Maggioni et al., "Valsartan Reduces the Incidence of Atrial Fibrillation in the Patients with Heart Failure in the Val-HeFT Trial," Abstracts From Scientific Sessions 108(17 sup):IV-507 through IV-508 (2003)						
I.A.P./		Madrid et al., "Role of Angiotensin Receptor Blockers and/or Angiotensin-Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases. Meta-Analysis of Randomized Controlled Clinical Trials," Abstracts From Scientific Sessions 108(17 sup):IV-507 (2003)						
EXAMINER /Anna Pagonakis/				DATE CONSIDERED 09/18/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240	
				DUCHARME et al.			
				FILING 04/15/2004		GROUP ART 3762	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

U.S. PATENT APPLICATION PUBLICATIONS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
I.A.P./			Alsheikh-Ali et al., "Enalapril Treatment and Hospitalization for Atrial Tachyarrhythmias in Patients with Left Ventricular Dysfunction," Abstracts From Scientific Sessions 108(17 sup):IV-423 (2003)
I.A.P./			Pedersen et al., "Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients with Left Ventricular Dysfunction," Circulation 100:376-80 (1999)

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 09/18/2007
------------------------------	-------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional)	Application Number
		5197-103 US	10/826,240
		Applicant(s) DUCHARME et al.	
		Filing Date	Group Art Unit
		04/15/2004	3762
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
http://www.aboutatrialfibrillation.com/whatisaf.html			
I.A.P./	1		
	2	CARSON, Peter E. et al., "The Influence of Atrial Fibrillation on Prognosis in Mild to Moderate Heart Failure - The V-HeFT Studies", Circulation, Supplement VI, 87:6, pp VI102-VI110, (June 1993);	
I.A.P./	3	MIDDLEKAUFF, Holly R. et al., "Prognostic Significance of Atrial Fibrillation in Advanced Heart Failure - A Study of 390 Patients", Circulation, 84:1, pp 40-48, (July 1991);	
I.A.P./	4	POZZOLI, Massimo et al., "Predictors of Primary Atrial Fibrillation and Concomitant Clinical and Hemodynamic Changes in Patients With Chronic Heart Failure: A Prospective Study in 344 Patients With Baseline Sinus Rhythm", JACC, 32:1, pp 197-204, (July 1998);	
I.A.P./	5	DRIES, Daniel L. et al., "Atrial Fibrillation Is Associated With an Increased Risk for Mortality and Heart Failure Progression in Patients With Asymptomatic and Symptomatic Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SOLVD Trials", JACC, 32:3, pp 695-703, (September 1998);	
I.A.P./	6	BOURASSA, Martial G. et al., "Natural History and Patterns of Current Practice in Heart Failure", JACC, Supplement A, 22:4, pp 14A-19A, (October 1993);	
I.A.P./	7	MATHEW, James et al., "Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias, in Congestive Heart Failure", CHEST, 118:4, 914-922, (October 2000);	
I.A.P./	8	LI, Danshi et al., "Promotion of Atrial Fibrillation by Heart Failure in Dogs - Atrial Remodeling of a Different Sort", Circulation, 100, pp 87-95, (July 6, 1999);	
I.A.P./	9	SHI, Yanfen et al., "Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation", Cardiovascular Research, 52, pp 219-225, (2001);	
I.A.P./	10	LI, Danshi et al., "Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing-Induced Congestive Heart Failure", Circulation, 104, pp 2608-2614, (November 20, 2001);	
I.A.P./	11	SHI, Yanfen et al., "Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure", Cardiovascular Research, 54, pp 456-461, (2002);	
I.A.P./	12	THE SOLVD INVESTIGATORS, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure", The New England Journal of Medicine, 325:5, pp 293-302, (August 1, 1991);	
EXAMINER		DATE CONSIDERED	
/Anna Pagonakis/		09/18/2007	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			


INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 5197-103 US	Application Number 10/862,240
		Applicant(s) DUCHARME et al.	
		Filing Date 04/15/2004	Group Art Unit 3762

*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
I.A.P./	13	THE SOLVD INVESTIGATORS, "Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions", The New England Journal of Medicine, 327:10, pp 685-691, (September 3, 1992);
I.A.P./	14	THE SOLVD INVESTIGATORS, "Studies of Left Ventricular Dysfunction (SOLVD) - Rationale, Design and Methods: Two Trials That Evaluate the Effect of Enalapril on Patients with Reduced Ejection Fraction", The American Journal of Cardiology, 66, pp 315-322, (August 1, 1990);
I.A.P./	15	FUSTER, Valentin et al., "ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary", JACC, 38:4, pp 1231-1265, (October 2001);
I.A.P./	16	ST. JOHN SUTTON, Martin et al., "Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction - The Protective Effects of Captopril", Circulation, 89:1, pp 68-75, (January 1994);
I.A.P./	17	ZOU, Yunzeng et al., "Cell Type-Specific Angiotensin II-Evoked Signal Transduction Pathways - Critical Roles of G Subunit, Src Family, and Ras in Cardiac Fibroblasts", Circ. Res., 82, pp 337-345, (1998);
I.A.P./	18	PAGES, Gilles et al., "Mitogen-activated protein kinases p42 and p44 are required for fibroblast proliferation", Proc. Nat. Acad. Sci., 90, pp 8319-8323, (September 1993);
I.A.P./	19	BRILLA, Christian G. et al., "Collagen Metabolism in Cultured Adult Rat Cardiac Fibroblasts: Response to Angiotensin II and Aldosterone", J. Mol. Cell Cardiol., 26, pp 809-820, (1994);
I.A.P./	20	GOETTE, Andreas et al., "Increased Expression of Extracellular Signal-Regulated Kinase and Angiotensin-Converting Enzyme in Human Atria During Atrial Fibrillation", JACC, 35:6, pp 1669-1677, (May 2000);
I.A.P./	21	GOTTE, Andreas et al., "Regulation of Angiotensin II Receptor Subtypes During Atrial Fibrillation in Humans", Circulation, 101, pp 2678-2681, (June 13, 2000);
I.A.P./	22	NAKASHIMA, Hideko et al., "Angiotensin II Antagonist Prevents Electrical Remodeling in Atrial Fibrillation", Circulation, 101, pp 2612-2617, (June 6, 2000);
I.A.P./	23	KAPRIELIAN, Raffi R. et al., "Angiotensin II Receptor Type 1 mRNA is Upregulated in Atria of Patients with End-stage Heart Failure", J. Mol. Cell. Cardiol., 29, pp 2299-2304, (1997);
I.A.P./	24	SOLTI, F. et al., "The effect of atrial dilatation on the genesis of atrial arrhythmias", Cardiovascular Research, 23, pp 882-886, (1989);

EXAMINER <div style="text-align: center;">/Anna Pagonakis/</div>	DATE CONSIDERED <div style="text-align: center;">09/18/2007</div>
-------------------------------------------------------------------------	--------------------------------------------------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 5197-103 US	Application Number 10/826,240
		Applicant(s) DUCHARME et al.	
		Filing Date 04/15/2004	Group Art Unit 3762
*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
/A.P./	25	RAVELLI, Flavia et al., "Effects of Atrial Dilatation on Refractory Period and Vulnerability to Atrial Fibrillation in the Isolated Langendorff-Perfused Rabbit Heart", Circulation, 96:5, pp 1686-1695, (September 2, 1997);	
/A.P./	26	WEBSTER, Mark W.I. et al., "Effect of Enalapril on Ventricular Arrhythmias in Congestive Heart Failure", The American Journal of Cardiology, 56, pp 566-569, (September 15, 1985);	
/A.P./	27	MADRID, Antonio H. et al., "Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation - A Prospective and Randomized Study", Circulation, 106, 331-336, (July 16, 2002);	
/A.P./	28	LAMASSA, Maria et al., "Characteristics, Outcome, and Care of Stroke Associated With Atrial Fibrillation in Europe: Data From a Multicenter Multinational Hospital-Based Registry (The European Community Stroke Project)", Stroke, 32, pp 392-398, (February 2001);	
/A.P./	29	BOSCH, Jackie et al., "Use of ramipril in preventing stroke: double blind randomised trial", BMJ, 324, pp 1-5, (March 23, 2002);	
/A.P./	30	SHINAGAWA, Kaori et al., "Dynamic Nature of Atrial Fibrillation Substrate During Development and Reversal of Heart Failure in Dogs", Circulation, 105, pp 2672-2678, (June 4, 2002);	
/A.P./	31	UENG, Kwo-Chang et al., "Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation - Results of a prospective and controlled study", European Heart Journal, 24, pp 2090-2098, (2003);	
/A.P./	32	THE AF-CHF TRIAL INVESTIGATORS, "Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial", American Heart Journal, 144:4 pp 597-607, (October 2002);	
/A.P./	33	THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", The New England Journal of Medicine, 342:3, pp 145-153, (January 20, 2000).	
EXAMINER /Anna Pagonakis/		DATE CONSIDERED 09/18/2007	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240		
				APPLICANT(S) DUCHARME et al.				
				FILING DATE 04/15/2004		GROUP ART UNIT 3762		
				U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
I.A.P./		Van Den Berg et al., "Effects of Lisinopril in Patients with Heart Failure and Chronic Atrial Fibrillation," J Cardiac Failure 1(5):355-63 (1995)						
I.A.P./		Van Noord et al., "Pre-Treatment with ACE Inhibitors Enhances Cardioversion Outcome in Patients with Persistent Atrial Fibrillation," Abstracts From Scientific Sessions 104(17 sup):II-699 (2001)						
EXAMINER /Anna Pagonakis/				DATE CONSIDERED 09/18/2007				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 20 2004

PATENT & TRADEMARK OFFICE

ATTY DOCKET NO.
4943-108 US

APPLICATION NO.
10/826,240

DUCHARME et al.

FILING
04/15/2004

GROUP ART
3762

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/A.P./		Stevenson et al., "Improving Survival for Patients with Atrial Fibrillation and Advanced Heart Failure," JACC 28(6):1458-63 (1996)
/A.P./		Vermes et al., "Enalapril Decreases the Incidence of Atrial Fibrillation in Patients with Left Ventricular Dysfunction," Circulation 107:2926-2931 (2003)

EXAMINER /Anna Pagonakis/

DATE CONSIDERED 09/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240		
				DUCHARME et al.				
				FILING 04/15/2004		GROUP ART 3762		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
/A.P./		Maggioni et al., "Valsartan Reduces the Incidence of Atrial Fibrillation in the Patients with Heart Failure in the Val-HeFT Trial," Abstracts From Scientific Sessions 108(17 sup):IV-507 through IV-508 (2003)						
/A.P./		Madrid et al., "Role of Angiotensin Receptor Blockers and/or Angiotensin-Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases. Meta-Analysis of Randomized Controlled Clinical Trials," Abstracts From Scientific Sessions 108(17 sup):IV-507 (2003)						
EXAMINER /Anna Pagonakis/				DATE CONSIDERED 09/18/2007				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <small>(Use several sheets if necessary)</small>				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240	
				DUCHARME et al.			
				FILING 04/15/2004		GROUP ART 3762	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	


U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <small>(Including Author, Title, Date, Pertinent Pages, Etc.)</small>		
/A.P./		Alsheikh-Ali et al., "Enalapril Treatment and Hospitalization for Atrial Tachyarrhythmias in Patients with Left Ventricular Dysfunction," Abstracts From Scientific Sessions 108(17 sup):IV-423 (2003)
/A.P./		Pedersen et al., "Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients with Left Ventricular Dysfunction," Circulation 100:376-80 (1999)

EXAMINER /Anna Pagonakis/	DATE CONSIDERED 09/18/2007
-------------------------------------	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

				ATTY DOCKET NO. 4943-108 US		APPLICATION NO. 10/826,240		
				DUCHARME et al.				
				FILING 04/15/2004		GROUP ART 3762		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
U.S. PATENT APPLICATION PUBLICATIONS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
/A.P./		Naccarelli et al., "Old and New Antiarrhythmic Drugs for Converting and Maintaining Sinus Rhythm in Atrial Fibrillation: Comparative Efficacy and Results of Trials," Am J Cardiol 91(6a sup):15D-26D (2003)						
EXAMINER /Anna Pagonakis/				DATE CONSIDERED 09/18/2007				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								